Abstract
The combination of biomaterials and drug delivery strategies is a promising avenue towards improved synthetic bone substitutes. With the delivery of active species biomaterials can be provided with the bioactivity they still lack for improved bone regeneration. Recently, a lot of research efforts have been put towards this direction. Biomaterials for bone regeneration have been supplemented with small or biological molecules for improved osteoprogenitor cell recruitment, osteoinductivity, anabolic or angiogenic response, regulation of bone metabolism and others. The scope of this review is to summarize the most recent results in this field.
Keywords: Biomaterials, bone defects, bone regeneration, drug delivery, growth factors, scaffolds, small molecules, synthetic bone substitutes.
Current Pharmaceutical Biotechnology
Title:Bone Regeneration with Biomaterials and Active Molecules Delivery
Volume: 16 Issue: 7
Author(s): Matteo D`Este, David Eglin, Mauro Alini and Laura Kyllonen
Affiliation:
Keywords: Biomaterials, bone defects, bone regeneration, drug delivery, growth factors, scaffolds, small molecules, synthetic bone substitutes.
Abstract: The combination of biomaterials and drug delivery strategies is a promising avenue towards improved synthetic bone substitutes. With the delivery of active species biomaterials can be provided with the bioactivity they still lack for improved bone regeneration. Recently, a lot of research efforts have been put towards this direction. Biomaterials for bone regeneration have been supplemented with small or biological molecules for improved osteoprogenitor cell recruitment, osteoinductivity, anabolic or angiogenic response, regulation of bone metabolism and others. The scope of this review is to summarize the most recent results in this field.
Export Options
About this article
Cite this article as:
D`Este Matteo, Eglin David, Alini Mauro and Kyllonen Laura, Bone Regeneration with Biomaterials and Active Molecules Delivery, Current Pharmaceutical Biotechnology 2015; 16 (7) . https://dx.doi.org/10.2174/1389201016666150206112121
DOI https://dx.doi.org/10.2174/1389201016666150206112121 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery Bioactive Compounds Containing Benzoxadiazole, Benzothiadiazole, Benzotriazole
Current Bioactive Compounds Anticancer Drugs in Liposomal Nanodevices: A Target Delivery for a Targeted Therapy
Current Topics in Medicinal Chemistry Updates on the Production of Therapeutic Antibodies Using Human Hybridoma Technique
Current Pharmaceutical Design Histone Deacetylases: Anti-Angiogenic Targets in Cancer Therapy
Current Cancer Drug Targets Mouse Models of Autoimmune Uveitis
Current Pharmaceutical Design Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes
Current Pharmaceutical Design Involvement of Targeting and Scaffolding Proteins in the Regulation of the EGFR/Ras/MAPK Pathway in Oncogenesis
Current Signal Transduction Therapy The Role of Downstream Signaling Pathways of the Epidermal Growth Factor Receptor for Artesunates Activity in Cancer Cells
Current Cancer Drug Targets Nanomedicine to Deal With Cancer Cell Biology in Multi-Drug Resistance
Mini-Reviews in Medicinal Chemistry Current Status and Perspectives Regarding the Treatment of Osteosarcoma: Chemotherapy
Reviews on Recent Clinical Trials Drug-Induced Peripheral Neuropathy: Diagnosis and Management
Current Cancer Drug Targets Intracellular Logistics of BST-2/Tetherin
Current HIV Research Targeting Microtubules for Cancer Chemotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Highly Selective MEK Inhibitors
Current Enzyme Inhibition Biosafety of Lentiviral Vectors
Current Gene Therapy T Cell Tuning for Tumour Therapy: Enhancing Effector Function and Memory Potential of Therapeutic T cells
Current Gene Therapy ACE2/Angiotensin-(1-7)/Mas Receptor Axis in Human Cancer: Potential Role for Pediatric Tumors
Current Drug Targets Non-Viral Nucleic Acid Delivery: Key Challenges and Future Directions
Current Drug Delivery Polyketide Natural Products, Acetogenins from Graviola (Annona muricata L), its Biochemical, Cytotoxic Activity and Various Analyses Through Computational and Bio-Programming Methods
Current Pharmaceutical Design